BioSpace News Archive

Centogene N.V. announced that it has signed an agreement with PTC Therapeutics, Inc. for a global diagnostic program for aromatic L-amino acid decarboxylase deficiency.

He will assume oversight of the Company’s finance function and financial reporting while the Company conducts its national search for a permanent CFO.

UroGen Pharma Ltd. announced that it will participate in fireside chats at the following conferences in November

Highlights the Proper Experimental Design and Reporting Required for Accurate Biomarker Prediction Performance

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, emphasized the significance of the new updated report from the Centers for Disease Control and Prevention (CDC) concerning the rise of antibiotic resistance.

LHC Group, Inc. (NASDAQ: LHCG) announced today that the Company is presenting at the 2019 Jefferies London Healthcare Conference in London, England on Wednesday, November 20, 2019 at 9:20 a.m. Greenwich Mean Time and a live webcast will be available.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxxwill participate in a fireside chat and host one-on-one meetings with investors at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019 at the Lotte New York Palace in New York, NY.

Phio Pharmaceuticals Corp. announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock, at a public offering price per share of $0.10, for gross proceeds of $1.0 million, before deducting placement agent fees and other offering expenses.

KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically poor clinical outcomes.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference, being held at the Waldorf Hilton on Aldwych, in London, UK